title: Severe myopia as a risk factor for progressive visual field loss in primary open-angle glaucoma.
abstract: The optic nerve head in severely myopic eyes may be particularly vulnerable to glaucomatous damage. To study this hypothesis, we examined 122 primary open-angle glaucoma eyes with fair to good control of the intraocular pressure and a sign of baseline optic nerve damage. Then, parameters for the progression of the visual field defects were evaluated by multivariate analysis. A high mean intraocular pressure (p = 0.007) and a large refractive error (p = 0.023) were significant risk factors for subsequent visual field loss. A high baseline cup-to-disk ratio (p = 0.100) was a marginal risk factor. Nonsignificant parameters included patient age (p = 0.692), the use of beta-adrenergic antagonists (p = 0.384), gender (p = 0.831) and left versus right side (p = 0.977). When the refractive error was used to subclassify patients into severely myopic (< or = -4 dpt), mildly myopic (-0.25 to -4 dpt), or emmetropic and hyperopic (> or = 0 dpt), only severe myopia was a significant risk factor for progressive visual field loss. Severe myopia, but not mild myopia, is a significant risk factor for subsequent visual field loss in patients with primary open-angle glaucoma.
authors.affiliation: Sensho-Kai Eye Hospital, Kyoto, Japan.
authors.forename: E
authors.initials: E
authors.lastname: Chihara
authors.forename: X
authors.initials: X
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Dong
authors.forename: Y
authors.initials: Y
authors.lastname: Takashima
authors.forename: M
authors.initials: M
authors.lastname: Akimoto
authors.forename: M
authors.initials: M
authors.lastname: Hangai
authors.forename: S
authors.initials: S
authors.lastname: Kuriyama
authors.forename: H
authors.initials: H
authors.lastname: Tanihara
authors.forename: M
authors.initials: M
authors.lastname: Hosoda
authors.forename: S
authors.initials: S
authors.lastname: Tsukahara
mesh_terms: D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D009898:Optic Disk / Q000473:pathology; D012307:Risk Factors; D014786:Vision Disorders / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D014794:Visual Fields
chemical_list: D000319:Adrenergic beta-Antagonists